Table 1.
Baseline characteristics of study subjects before pravastatin treatment
| Characteristic | SLCO1B1521TT group(n = 36) | SLCO1B1521TC group(n = 9) | P-value |
|---|---|---|---|
| Age (years) | 65.8 ± 11.2 | 66.3 ± 8.81 | 0.70 |
| Sex (M/F) | 22/14 | 6/3 | – |
| Body mass index (kg m−2) | 25.49 ± 3.45 | 24.78 ± 2.65 | 0.54 |
| Medication | |||
| Aspirin | 29 (81%) | 7 (78%) | 0.85 |
| β-blocker | 25 (69%) | 6 (67%) | 0.87 |
| Calcium antagonists | 17 (47%) | 5 (56%) | 0.66 |
| Angiotensin-converting enzyme inhibitors | 22 (61%) | 5 (56%) | 0.76 |
| Nitrates | 20 (56%) | 6 (67%) | 0.55 |
| Clopidogrel | 15 (42%) | 3 (33%) | 0.65 |
| Total cholesterol (mmol l−1) | 5.47 ± 1.15 | 5.52 ± 0.51 | 0.11 |
| LDL-cholesterol (mmol l−1) | 3.67 ± 0.91 | 3.63 ± 0.15 | 0.64 |
| HDL-cholesterol (mmol l−1) | 1.15 ± 0.37 | 1.01 ± 0.35 | 0.76 |
| Triglycerides (mmol l−1) | 1.96 ± 0.85 | 2.34 ± 1.66 | 0.12 |
Data are shown as mean±SD. LDL, Low-density lipoprotein; HDL, high-density lipoprotein.